AI Insight
This commentary addresses the challenge of determining optimal treatment sequences for patients with advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs). While these somatostatin receptor-positive, well-differentiated tumours typically progress slowly, clinicians must eventually make treatment decisions that balance disease control against side effects, patient quality of life, and maintaining future treatment options. The authors highlight that establishing evidence-based treatment sequencing strategies remains an important unmet need in the clinical management of this patient population.
Why it matters
Improved treatment sequencing guidelines could help oncologists maximize patient survival and quality of life by making more informed decisions about when to initiate specific therapies and which treatments to reserve for later-stage disease. This is particularly relevant as multiple treatment options become available for GEP-NETs, making the order of intervention increasingly complex and consequential.
Understand the Science
Treatment sequencing in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) remains a major unmet clinical need.1 Although somatostatin receptor-positive, well differentiated GEP-NETs often follow a somewhat indolent course, disease progression eventually requires treatment decisions that balance tumour control, toxicity, quality of life, and the preservation of future therapeutic options.
Source: [Comment] Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours